tbuckley/cabot-search huggingface dataset:
Evolution of the Mutational Process under Relaxed Selection in<i>Caenorhabditis elegans</i>
Authors: Ayush Shekhar Saxena, Matthew P Salomon, Chikako Matsuba, Shu-Dan Yeh, Charles F Baer
Journal: Molecular Biology and Evolution (2018)

The mutational process varies at many levels, from within genomes to among taxa. Many mechanisms have been linked to variation in mutation, but understanding of the evolution of the mutational process is rudimentary. Physiological condition is often implicated as a source of variation in microbial mutation rate and may contribute to mutation rate variation in multicellular organisms. Deleterious mutations are an ubiquitous source of variation in condition. We test the hypothesis that the mutational process depends on the underlying mutation load in two groups of Caenorhabditis elegans mutation accumulation (MA) lines that differ in their starting mutation loads. "First-order MA" (O1MA) lines maintained under minimal selection for ∼250 generations were divided into high-fitness and low-fitness groups and sets of "second-order MA" (O2MA) lines derived from each O1MA line were maintained for ∼150 additional generations. Genomes of 48 O2MA lines and their progenitors were sequenced. There is significant variation among O2MA lines in base-substitution rate (µbs), but no effect of initial fitness; the indel rate is greater in high-fitness O2MA lines. Overall, µbs is positively correlated with recombination and proximity to short tandem repeats and negatively correlated with 10 bp and 1 kb GC content. However, probability of mutation is sufficiently predicted by the three-nucleotide motif alone. Approximately 90% of the variance in standing nucleotide variation is explained by mutability. Total mutation rate increased in the O2MA lines, as predicted by the "drift barrier" model of mutation rate evolution. These data, combined with experimental estimates of fitness, suggest that epistasis is synergistic.
The potential impact of azithromycin in idiopathic pulmonary fibrosis
Authors: Claudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, Ritesh Chaube, Felix Chua, Athol U. Wells, Toby M. Maher, Peter M. George, Elizabeth A. Renzoni, Philip L. Molyneaux
Journal: European Respiratory Journal (2018)

<b>Prophylactic azithromycin is a safe and well tolerated therapy in patients with IPF and may reduce hospital admissions. Prospective mechanistic studies are urgently needed.</b>http://ow.ly/oBOn30mDaaL
HALO 110-101: Phase Ib study of PEGPH20 in combination with cisplatin + gemcitabine (PEGCISGEM) or atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in patients with locally advanced/metastatic cholangiocarcinoma and gallbladder cancer
Authors: D.-Y. Oh, J.-O. Park, C. Charoentum, S. Stein, M. Noel, V. Chung, W. Wu, R. Alton, M. Muhsin, M. Javle, G.K. Abou-Alfa, M.J. Borad
Journal: Annals of Oncology (2018)
LRP10 in α-synucleinopathies
Authors: Rita Guerreiro, Tatiana Orme, João Luís Neto, Jose Bras, Rita Guerreiro, John Hardy, Celia Kun-Rodrigues, Lee Darwent, Tatiana Orme, Joao Neto, Susana Carmona, Olaf Ansorge, Laura Parkkinen, Kevin Morgan, Kristelle Brown, Anne Braae, Imelda Barber, Claire Troakes, Safa Al-Sarraj, Tammaryn Lashley, Janice Holton, Yaroslau Compta, Tamas Revesz, Andrew Lees, Henrik Zetterberg, Valentina Escott-Price, Stuart Pickering-Brown, David Mann, Andrew Singleton, Dena Hernandez, Owen Ross, Dennis Dickson, Neill Graff-Radford, Tanis Ferman, Ronald Petersen, Brad Boeve, Michael Heckman, John Q. Trojanowski, Vivianna Van Deerlin, Nigel Cairns, John Morris, David A. Stone, John Eicher, Lorraine Clark, Lawrence Honig, Karen Marder, Geidy Serrano, Thomas Beach, Douglas Galasko, Eliezer Masliah, Ekaterina Rogaeva, Peter St. George-Hyslop, Jordi Clarimon, Alberto Lleo, Estrella Morenas-Rodriguez, Pau Pastor, Monica Diez-Fairen, Miquel Aquilar, Claire Shepherd, Glenda Halliday, Pentti Tienari, Liisa Myllykangas, Minna Oinas, Isabel Santana, Suzanne Lesage, Elisabet Londos, Afina Lemstra, Jose Bras
Journal: The Lancet Neurology (2018)
Can fairer sex, febrile neutropenia & compliance influence surviving probability in non-metastatic osteosarcoma: Experience over two decades from India
Authors: J. Bajpai, V. Simha, A. Chandrashekharan, J. Ghosh, B. Rekhi, T. Vora, S. Banavali, S. Gupta
Journal: Annals of Oncology (2018)
Failure to sense energy depletion may be a novel therapeutic target in chronic kidney disease
Authors: Hiroaki Kikuchi, Emi Sasaki, Naohiro Nomura, Takayasu Mori, Yoji Andrew Minamishima, Yuki Yoshizaki, Naohiro Takahashi, Taisuke Furusho, Yohei Arai, Shintaro Mandai, Takahiro Yamashita, Fumiaki Ando, Yasuhiro Maejima, Kiyoshi Isobe, Tomokazu Okado, Tatemitsu Rai, Shinichi Uchida, Eisei Sohara
Journal: Kidney International (2018)
Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Authors: Jingru Jiang, Yi Li, Qingyu Shen, Xiaoming Rong, Xiaolong Huang, Honghong Li, Lizhi Zhou, Hai-Qiang Mai, Dong Zheng, Ming-Yuan Chen, Yongteng Xu, Jibin Li, Xuan Hui, Charles B. Simone, Jan Gaertner, Andreas A. Argyriou, Edward Chow, Pingyan Chen, Yamei Tang
Journal: Journal of Clinical Oncology (2018)

Purpose Neuropathic pain is an unavoidable treatment-related adverse event among patients with head and neck cancer who are undergoing radiotherapy. We aimed to test the efficacy and safety of pregabalin versus placebo in the treatment of radiotherapy-related neuropathic pain. Patients and Methods This randomized, double-blind, placebo-controlled trial was conducted in four centers in China. Eligible patients with a mean pain intensity score of 4 or more on an 11-point numeric rating scale were randomly assigned to receive either active treatment with a flexible dose of pregabalin or placebo for 16 weeks. The primary efficacy outcome was pain reduction measured on the numeric rating scale. Result There were 128 patients who received treatment as randomly assigned. Pain intensity reduction was 2.44 in the pregabalin arm and 1.58 in the placebo arm at week 16, yielding an adjusted mean difference of 0.87 (95% CI, 0.30 to 1.44; P = .003). In the pregabalin arm, 38 patients (59.4%) achieved at least 30% pain relief versus 21 (32.8%) in the placebo arm ( P = .006). Nineteen patients (29.7%) in the pregabalin group and five (7.8%) in the placebo group achieved 50% or greater pain relief ( P = .003). Total scores on the Profile of Mood States-Short Form, pain severity and functional interference of Brief Pain Inventory-Short Form, as well as the physiology and psychology domain of the WHO Quality of Life-BREF all were reduced significantly at week 16 in patients who received pregabalin compared with those who received placebo. There was no significant difference ( P = .29) in the incidence of experiencing at least one adverse event in the pregabalin arm (n = 35; 54.7%) versus the placebo arm (n = 29; 45.3%). Conclusion Patients treated with pregabalin with radiotherapy-related neuropathic pain had greater pain alleviation, better mood states, and higher quality of life compared with patients in the placebo group, with a good tolerability.
Engaging with stakeholders to inform the development of a computer model for the NHS Health Check programme: a qualitative study
Authors: Lirije Hyseni, Maria Guzman-Castillo, Chris Kypridemos, Brendan Collins, Ellen Schwaller, Simon Capewell, Angela Boland, Rumona Dickson, Martin O'Flaherty, Ffion Lloyd-Williams
Journal: The Lancet (2018)
Disparities in the Diagnosis and Treatment of Lung Cancer among People with Disabilities
Authors: Dong Wook Shin, Jong Ho Cho, Jae Myoung Noh, Hyesook Han, Kyungdo Han, Sang Hyun Park, So Young Kim, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi
Journal: Journal of Thoracic Oncology (2018)
Abstract 17404: New Insights into Mechanisms of Right Ventricular Dysfunction in Tetralogy of Fallot: Regional Post-Systolic Shortening is Associated with Right Ventricular Dysfunction and Dyssynchrony
Authors: Wei Hui, Cameron Slorach, Tim Bradley, Edgar Jaeggi, Luc Mertens, Mark Friedberg
Journal: Circulation (2012)

Background Regional right ventricular (RV) dysfunction is recognized as a key determinant of global RV function and outcomes after tetralogy of Fallot repair (rTOF). Regional left ventricular contr...
Cross‐sectional associations between cutaneous viral infections and regulatory T lymphocytes in circulation
Authors: S.S. Hampras, M. Tommasino, Y. Zhao, J.L. Messina, A.R. Giuliano, N.A. Fenske, B. Cherpelis, R.S. Hesterberg, A.A. Akuffo, R.P. Amorrortu, J. Balliu, L. Vijayan, T. Gheit, P.K. Epling‐Burnette, D.E. Rollison
Journal: British Journal of Dermatology (2018)

Cutaneous viral infections and immune suppression are risk factors for some forms of nonmelanoma skin cancer; however, their interrelationship is poorly understood.
Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: A meta-analysis of results from multivariate analysis
Authors: Jinan Guo, Jiequn Fang, Xiangjiang Huang, Yanfeng Liu, Yeqing Yuan, Xueqi Zhang, Chang Zou, Kefeng Xiao, Jianhong Wang
Journal: International Journal of Surgery (2018)
Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy
Authors: Victor A. Chow, Ajay K. Gopal, David G. Maloney, Cameron J. Turtle, Stephen D. Smith, Mazyar Shadman, Ryan D. Cassaday, Brian G. Till, Yolanda D. Tseng, Edus H. Warren, Andrei R. Shustov, Manoj P. Menon, Sandra Kanan, Utkarsh H. Acharya, Erin Mullane, Lindsay M. Hannan, Jenna M. Voutsinas, Ted Gooley, Ryan C. Lynch
Journal: Blood (2018)
Sensitivity and Specificity of Autoantibodies Against <scp>CD</scp>74 in Nonradiographic Axial Spondyloarthritis
Authors: Elke Riechers, Niklas Baerlecken, Xenofon Baraliakos, Katrin Achilles‐Mehr Bakhsh, Peer Aries, Bettina Bannert, Klaus Becker, Jan Brandt‐Jürgens, Jürgen Braun, Boris Ehrenstein, Hans‐Hartwig Euler, Martin Fleck, Reinhard Hein, Kirsten Karberg, Lars Köhler, Torsten Matthias, Regina Max, Adelheid Melzer, Dirk Meyer‐Olson, Jürgen Rech, Karin Rockwitz, Martin Rudwaleit, Reinhold E. Schmidt, Eva Schweikhard, Joachim Sieper, Carsten Stille, Ulrich von Hinüber, Peter Wagener, Heike‐Franziska Weidemann, Silke Zinke, Torsten Witte
Journal: Arthritis & Rheumatology (2018)

Objective Autoantibodies against CD 74 (anti‐ CD 74) are associated with ankylosing spondylitis ( AS ). The present multicenter study, the International Spondyloarthritis Autoantibody (InterSpA) trial, was undertaken to compare the sensitivity and specificity of anti‐ CD 74 and HLA –B27 in identifying patients with nonradiographic axial spondyloarthritis (axSpA). Methods Patients ages 18–45 years with inflammatory back pain of ≤2 years’ duration and a clinical suspicion of axSpA were recruited. HLA –B27 genotyping and magnetic resonance imaging of sacroiliac joints were performed in all patients. One hundred forty‐nine patients with chronic inflammatory back pain ( IBP ) not caused by axSpA served as controls, and additional controls included 50 AS patients and 100 blood donors whose specimens were analyzed. Results One hundred patients with inflammatory back pain received a diagnosis of nonradiographic axSpA from the investigators and fulfilled the Assessment of SpondyloArthritis international Society ( ASAS ) criteria. The mean age was 29 years, and the mean symptom duration was 12.5 months. The sensitivity of IgA anti‐ CD 74 and IgG anti‐ CD 74 for identifying the 100 axSpA patients was 47% and 17%, respectively. The specificity of both IgA anti‐ CD 74 and IgG anti‐ CD 74 was 95.3%. The sensitivity of HLA –B27 was 81%. The positive likelihood ratios were 10.0 (IgA anti‐ CD 74), 3.6 (IgG anti‐ CD 74), and 8.1 ( HLA –B27). Assuming a 5% pretest probability of axSpA in chronic back pain patients, the posttest probability, after consideration of the respective positive test results, was 33.3% for IgA anti‐ CD 74, 15.3% for IgG anti‐ CD 74, and 28.8% for HLA –B27. A combination of IgA anti‐ CD 74 and HLA –B27 results in a posttest probability of 80.2%. Conclusion IgA anti‐ CD 74 may be a useful tool for identifying axSpA. The diagnostic value of the test in daily practice requires further confirmation.
Abstract 9739: Predictive Values of ST-segment Elevation in Lead aVR for the Diagnosis of Left Main or 3-Vessel Disease in Patients With Non-ST-segment Elevation Acute Coronary Syndrome
Authors: Masami Kosuge, Toshiaki Ebina, Kiyoshi Hibi, Kengo Tsukahara, Noriaki Iwahashi, Nobuhiko Maejima, Eiichi Akiyama, Satoshi Umemura, Kazuo Kimura
Journal: Circulation (2015)

Introduction: In patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), early identification of left main or 3-vessel disease (LM/3VD) is important in selecting the optimal treatment strategy. Hypothesis: ST-segment elevation in lead aVR (ST↑aVR) at presentation is considered a useful predictor of LM/3VD; however, time from symptom onset to presentation may influence its predictive value. Methods: We studied 835 patients with NSTE-ACS undergoing coronary angiography during hospitalization. We evaluated ECG findings and troponin T (TnT), estimated glomerular filtration rate (eGFR), brain natriuretic peptide (BNP), high-sensitivity C-reactive protein (hsCRP), and TIMI risk score on admission. Results: The prevalence of LM/3VD was 21%. Patients with LM/3VD were older (70±11 vs 66±11 yrs), had higher rates of hypertension (72% vs 64%), diabetes mellitus (51% vs 30%), Killip class ≥2 (31% vs 6%), positive-troponin T (≥0.1 ng/ml) (57% vs 29%), and ST↑aVR ≥0.5 mm (79% vs 15%), and had higher levels of BNP (367±407 vs 184±398 pg/ml), hsCRP (0.908±2.564 vs 0.371±1.425 mg/dl), and summed ST-segment depression (9±7 vs 2±3 mm), and TIMI risk score (3.7±1.2 vs 2.6±1.4) and a lower eGFR (54±27 vs 66±24 ml/min/1.73 m2), and a higher rate of in-hospital death, (re)infarction, or urgent revascularization (36% vs 9%) than did those without LM/3VD (all p&lt;0.05). Multivariate analysis showed that ST↑aVR (OR 10.8, 95%CI 3.88-20.1, p&lt;0.01) was the strongest predictor of LM/3VD, and followed by positive-troponin T (OR 2.20, 95%CI 1.26-4.01, p&lt;0.01). When patients were subdivided according to the 6-h time window from symptom onset, the predictive values of ST↑aVR for the diagnosis of LM/3VD were significantly higher than those of positive-troponin T, except the sensitivity in delayed presentation (Table). Conclusions: In patients with NSTE-ACS, ST↑aVR on admission strongly predicted LM/3VD; however, its sensitivity decreased in delayed (&gt;6 h) presentation.
Abstract 20754: Six Types of Drug-Eluting Stents, Including Cilostazol and Paclitaxel Dual-Coating Stent, Show the Similar Clinical Outcomes in Patients of St-Segment Elevation Myocardial Infarction
Authors: Kyounghoon Lee, Jeonggeun Moon, Woong Chol Kang, Seung Hwan Han
Journal: Circulation (2017)

Introduction: The Cilotax stent®, cilostazol and paclitaxel dual-coating stent (CPD-stent), was created for synergy effect to increase the anti-proliferative effect of paclitaxel and the anti-throm...
Large-scale associations between the leukocyte transcriptome and BOLD responses to speech differ in autism early language outcome subtypes
Authors: Michael V. Lombardo, Tiziano Pramparo, Vahid Gazestani, Varun Warrier, Richard A. I. Bethlehem, Cynthia Carter Barnes, Linda Lopez, Nathan E. Lewis, Lisa Eyler, Karen Pierce, Eric Courchesne
Journal: Nature Neuroscience (2018)
Abstract 15577: Elevated Serum Aspartate Transaminase as a Predictor of Early Mortality in Patients With Non-ST-Segment Elevation Myocardial Infarction
Authors: Sameer Arora, Melissa C Caughey, Jacob A Misenheimer, Wesley M Jones, Adam C Fish, Sidney C Smith, George A Stouffer, Prashant Kaul
Journal: Circulation (2017)

Introduction: Aspartate transaminase (AST) was used historically as a biomarker to detect myocardial injury. The utility of AST as a prognostic marker in patients with Non-ST elevation Myocardial I...
Publisher Correction: Allele-defined genome of the autopolyploid sugarcane Saccharum spontaneum L
Authors: Jisen Zhang, Xingtan Zhang, Haibao Tang, Qing Zhang, Xiuting Hua, Xiaokai Ma, Fan Zhu, Tyler Jones, Xinguang Zhu, John Bowers, Ching Man Wai, Chunfang Zheng, Yan Shi, Shuai Chen, Xiuming Xu, Jingjing Yue, David R. Nelson, Lixian Huang, Zhen Li, Huimin Xu, Dong Zhou, Yongjun Wang, Weichang Hu, Jishan Lin, Youjin Deng, Neha Pandey, Melina Mancini, Dessireé Zerpa, Julie K. Nguyen, Liming Wang, Liang Yu, Yinghui Xin, Liangfa Ge, Jie Arro, Jennifer O. Han, Setu Chakrabarty, Marija Pushko, Wenping Zhang, Yanhong Ma, Panpan Ma, Mingju Lv, Faming Chen, Guangyong Zheng, Jingsheng Xu, Zhenhui Yang, Fang Deng, Xuequn Chen, Zhenyang Liao, Xunxiao Zhang, Zhicong Lin, Hai Lin, Hansong Yan, Zheng Kuang, Weimin Zhong, Pingping Liang, Guofeng Wang, Yuan Yuan, Jiaxian Shi, Jinxiang Hou, Jingxian Lin, Jingjing Jin, Peijian Cao, Qiaochu Shen, Qing Jiang, Ping Zhou, Yaying Ma, Xiaodan Zhang, Rongrong Xu, Juan Liu, Yongmei Zhou, Haifeng Jia, Qing Ma, Rui Qi, Zhiliang Zhang, Jingping Fang, Hongkun Fang, Jinjin Song, Mengjuan Wang, Guangrui Dong, Gang Wang, Zheng Chen, Teng Ma, Hong Liu, Singha R. Dhungana, Sarah E. Huss, Xiping Yang, Anupma Sharma, Jhon H. Trujillo, Maria C. Martinez, Matthew Hudson, John J. Riascos, Mary Schuler, Li-Qing Chen, David M. Braun, Lei Li, Qingyi Yu, Jianping Wang, Kai Wang, Michael C. Schatz, David Heckerman, Marie-Anne Van Sluys, Glaucia Mendes Souza, Paul H. Moore, David Sankoff, Robert VanBuren, Andrew H. Paterson, Chifumi Nagai, Ray Ming
Journal: Nature Genetics (2018)
Abstract 12808: Public Access Defibrillation Has Great Impact on Outcomes After Pediatric Out-of-hospital Cardiac Arrest
Authors: Tatsuma Fukuda, Naoko Ohashi-Fukuda, Hiroaki Kobayashi, Masataka Gunshin, Yutaka Kondo, Naoki Yahagi
Journal: Circulation (2016)

Introduction: Use of automated external defibrillators (AEDs) has been recommended for pediatric out-of-hospital cardiac arrest (OHCA). Studies in adults suggest that public-access defibrillation (PAD) improves the outcomes after OHCA, but there have been no conclusive studies in children. Hypothesis: We assessed the hypothesis that PAD is associated with an increased chance of favorable outcomes after pediatric OHCA. Methods: This was a nationwide, population-based, propensity score-matched study of pediatric OHCA in Japan from January 1, 2011, to December 31, 2012, based on data from the All-Japan Utstein Registry. We included pediatric patients who experienced OHCA and received bystander CPR. The primary outcome was a favorable neurological state one month after OHCA defined as a Glasgow-Pittsburgh cerebral performance category (CPC) score of 1-2 (corresponding to a Pediatric CPC score of 1-3). The secondary outcomes included a neurologically favorable survival with a CPC score of 1 (corresponding to a Pediatric CPC score of 1), one-month survival, and prehospital return of spontaneous circulation (ROSC). Results: A total of 1,193 patients were included in the final cohort; 57 received PAD and 1,136 did not. Among 1,193 patients, 188 (15.8%) survived with a favorable neurological status one month after OHCA. The odds of neurologically favorable survival were significantly higher for patients receiving PAD after adjusting for potential confounders: propensity score matching, OR 3.17 (95%CI 1.40-7.17), and multivariable logistic regression modeling, OR 5.10 (95% CI 2.01-13.70). Similar findings were observed for the secondary outcomes. In subgroup analyses, there were no significant differences in neurologically favorable survival between PAD group and no PAD group in unwitnessed cohort (OR 7.76 [0.75-81.90]) and non-cardiac etiology cohort (OR6.65 [0.64-66.24]). Conclusions: In conclusion, PAD was associated with an increased chance of neurologically favorable survival after pediatric OHCA, except for unwitnessed cases and non-cardiac etiology cases.
Diagnosis and Treatment of Alcohol Use Disorder in Patients With End‐Stage Alcoholic Liver Disease
Authors: Fabio Caputo, Marco Domenicali, Mauro Bernardi
Journal: Hepatology (2018)

Between 14%‐30% of the world’s population is affected by alcohol use disorder (AUD), and excessive alcohol consumption represents the most common cause of liver disease in the western world. The clinical picture of alcoholic end‐stage liver disease is rendered extremely complex, as manifestations such as alcohol withdrawal syndrome, craving and physical dependence, as well as extrahepatic alcohol‐related diseases merge with the complications of advanced cirrhosis. This makes AUD recognition and assessment difficult and its management arduous as many drugs commonly used to treat complications such as alcohol withdrawal syndrome are often contraindicated by the presence of hepatic encephalopathy or hepatorenal syndrome. Reaching and maintaining abstinence represents the mainstay of managing patients with AUD and end‐stage liver disease. Psychosocial interventions are an essential component of treatment to reach these goals. However, these interventions alone often prove insufficient in AUD patients and even more frequently in those with end‐stage liver disease because of inadequate adherence due to poor functional and physical status. Pharmacological treatments need to be associated, but the available options are greatly limited in end‐stage liver disease because many GABA‐Ergic drugs can favor the development of hepatic encephalopathy, whereas drugs undergoing extensive liver metabolism should be avoided or used with the greatest caution. Because of these limitations, the management of end‐stage AUD is extremely challenging and requires an integrated multidisciplinary approach.
Smoking uptake in UK children: analysis of the UK Millennium Cohort Study
Authors: Anthony A Laverty, Filippos T Filippidis, David Taylor-Robinson, Christopher Millett, Andrew Bush, Nicholas S Hopkinson
Journal: Thorax (2018)

We used data from 11 577 children in the UK Millennium Cohort Study, collected at approximately 14 years of age (early teens), to assess characteristics associated with smoking, and generated regional estimates of numbers of smokers. 13.8% of UK early teens studied had ever smoked; 1.9% were current smokers. This corresponds to 2 28 136 and 39 653 (13–14 year olds) in the UK, respectively. Ever smoking risk increased if caregivers (26.0% vs 10.9%) or friends smoked (35.1% vs 4.0%), with a dose–response effect for friends’ smoking. Caregiver and peer-group smoking remain important drivers of child smoking uptake and thus important targets for intervention.
In persistent hypertension, low-dose triple-pill therapy increased the likelihood of achieving target BP at 6 mo
Authors: Anthony Donato
Journal: Annals of Internal Medicine (2018)

Source Citation Webster R, Salam A, de Silva HA, et al; TRIUMPH Study Group. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA. 2018;320:566-79. 30120478
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
Authors: Stephen T. Buckley, Tine A. Bækdal, Andreas Vegge, Stine J. Maarbjerg, Charles Pyke, Jonas Ahnfelt-Rønne, Kim G. Madsen, Susanne G. Schéele, Tomas Alanentalo, Rikke K. Kirk, Betty L. Pedersen, Rikke B. Skyggebjerg, Andrew J. Benie, Holger M. Strauss, Per-Olof Wahlund, Simon Bjerregaard, Erzsébet Farkas, Csaba Fekete, Flemming L. Søndergaard, Jeanett Borregaard, Marie-Louise Hartoft-Nielsen, Lotte Bjerre Knudsen
Journal: Science Translational Medicine (2018)

An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach.